TEMENOS
7.1.2020 09:32:05 CET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that BNP Paribas Securities Services has extended its license for Temenos Multifonds Global Accounting and Temenos Multifonds Global Investor. Temenos’ single, global software platform and integrated operating model will deliver localized accounting and reporting to underpin the management of BNP Paribas Securities Services’ fund administration operations.
BNP Paribas Securities Services has been a partner of Temenos for more than 20 years, initially deploying the Temenos Fund Administration platform in Luxembourg to replace its legacy architecture and deliver the fundamental scalability needed for BNP Paribas to rapidly onboard new countries onto the global platform. By using a scalable platform and enabling more automated exception-based processing, BNP Paribas Securities Services will benefit from greater operational efficiency, reduced costs and new growth opportunities.
As part of this long-standing strategic partnership, Temenos recently completed the integration of Temenos Multifonds Global Accounting into BNP Paribas Securities Services’ domestic fund administration business in France. Achieved in under two years, the project covered 1,300 fund accounts, representing over 20% of the total French market.
Alain Pochet, Head of Client Delivery at BNP Paribas Securities Services, commented: “We are delighted to continue this strategic, long-standing partnership with Temenos. Its investment in R&D means that we will continue to benefit from cutting-edge, next generation banking software, enabling us to enhance operational efficiency and streamline our operating model to enable us to quickly onboard new jurisdictions and grow our business over time.”
Max Chuard, CEO , Temenos, said: “It is a great privilege to continue our ongoing support of BNP Paribas Securities Services as they continue to optimize their global fund administration operations and enhance operational efficiency. Throughout this long-standing partnership, our goals have been consistently aligned to BNP Paribas’ who have adopted our market-leading products to enhance fund administration with sophisticated workflow, production and control techniques. With a 20-year track record for providing leading fund administration software that supports $7 trillion assets and more than 30,000 funds across 30 countries, Temenos has the blueprint for transformative software that delivers greater efficiencies, reduced costs and enables our clients to take advantage of future growth opportunities.”
– Ends –
About BNP Paribas
BNP Paribas Securities Services, a wholly
owned subsidiary of the BNP Paribas Group, is a leading global custodian
and securities services provider. Backed by the strength of the BNP
Paribas Group, we provide multi-asset post-trade and asset servicing
solutions for buy and sell-side market participants, corporates and
issuers. With a global reach covering 90+ markets, our network is one of
the most extensive in the industry, enabling clients to maximise their
investment opportunities worldwide.
https://securities.bnpparibas.com/
About Temenos
Temenos AG (SIX: TEMN), headquartered in
Geneva, is the world’s leader in banking software, partnering with banks
and other financial institutions to transform their businesses and stay
ahead of a changing marketplace. Over 3,000 banks across the globe,
including 41 of the top 50 banks, rely on Temenos to process both the
daily transactions and client interactions of more than 500 million
banking customers. Temenos offers cloud-native, cloud-agnostic front
office and core banking, payments, fund management and wealth management
software products enabling banks to deliver consistent, frictionless
customer journeys and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve industry-leading cost-income ratios of 25.2% and returns on equity of 25.0%, 2X better than the industry average. These clients also invest over 53% of their IT budget on growth and innovation versus maintenance, which is 2.5X the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005107/en/
Contact:
Media Contacts Jessica Wolfe & Grace Collins Temenos Global Public Relations Tel: +1 610 232 2793 & + 44 20 7423 3969 Email : press@temenos.com Alistair Kellie & Andrew Adie Newgate Communications on behalf of Temenos Tel: +44 20 7680 6550 Email: allnewgatetemenos@newgatecomms.com Simon Anderson Narrative on behalf of Temenos Tel: +44 (0)7393 636 982 Email: simon.anderson@narrative.uk.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom